^
Association details:
| Biomarker: | CD20 underexpression |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Empliciti (elotuzumab) (CS-1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Downregulation of Chemokine CCL20 Involved in Myeloma Cells Resistant to Elotuzumab and Lenalidomide
Published date:
04/21/2021
Excerpt:
Cell models which are resistant to Elotuzumab and lenalidomide (UR, UE, URE) were successfully constructed. CCL20 gene expression decreased in resistant myeloma cell lines and RRMM patients....The expression of CCL20 was decreased in lenalidomide and Elotuzumab resistant U266 cells and in RRMM patients. CCL20 could therefore possibly increase the sensitivity of lenalidomide and Elotuzumab.
DOI:
https://doi.org/10.2147/OTT.S300328
